Emerald
Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)
(“Emerald”) today announced that Northern Vine Canada Inc. (Northern
Vine), a wholly owned subsidiary of Emerald, will participate in an
educational series of seminars regarding cannabis testing solutions
hosted by Thermo Fisher Scientific. Jaclyn Thomson, PhD, Director of
R&D at Northern Vine, will provide a presentation on pesticide
residue and terpenes analysis methods for the series, called: “Cannabis
Testing One-Stop Analytical Solutions Seminar Series,” across Canada
during October 9-18.
The seminar series will
provide information to scientists establishing new cannabis testing
laboratory or scaling-up operations. The series includes four stops in
Montreal, Ottawa, Toronto, and Vancouver. Each seminar will cover:
Health Canada regulation updates, targeted and non-targeted pesticide
analysis, sample preparation tips for improving results, fast and
accurate heavy metal analysis to ppb levels, rapid mycotoxin analysis,
and cannabis potency testing.
“With nationwide
legalization on the horizon, I’m honored to participate in this seminar
series to share insights into how to comply with updated testing
regulations for the Canadian cannabis market,” said Dr. Thomson. “The
upcoming legal marketplace will create new opportunities for
laboratories, licensed producers, and start-ups. Through this series, we
hope to support and prepare these organizations to produce reliable
results and ensure every sample meets regulated safety standards.”
For
more information on Thermo Fisher Scientific’s complete cannabis
testing solutions for the legalized Canadian market, please visit www.thermofisher.com/CannabisTesting.
About Emerald Health Therapeutics, Inc.
Emerald
Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a
Licensed Producer under Canada’s Access to Cannabis for Medical
Purposes Regulations and produces and sells dried cannabis and cannabis
oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is
converting a licensed existing 1.1 million square foot greenhouse in
Delta, BC, and is in commercial production. It owns Agro-Biotech, a
Québec-based licensed cannabis grower with a 75,000 square foot indoor
facility and is planning to add a 500,000 square foot greenhouse in
Metro Vancouver. Emerald’s team is highly experienced in life sciences,
product development, large-scale agri-business, and marketing, and is
focused on developing value-added cannabis-based products with potential
wellness and medical benefits. Emerald is part of the Emerald Health group,
which is broadly focused on developing pharmaceutical, botanical, and
nutraceutical products that may provide wellness and medical benefits by
interacting with the human body’s endocannabinoid system.
I recently came across your blog and have been reading along. I thought I would leave my first comment for personal use production license health canada. I don't know what to say except that I have enjoyed reading.
ReplyDelete